BIOC - Biocept, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.3241
+0.0039 (+1.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3202
Open0.3239
Bid0.3200 x 800
Ask0.3274 x 1300
Day's Range0.3108 - 0.3270
52 Week Range0.2300 - 2.1100
Volume1,508,973
Avg. Volume6,418,257
Market Cap13.683M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.7770
Earnings DateMar 25, 2020 - Mar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
    PR Newswire

    Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J. Dunn, M.S., M. Ed. to Senior Vice President of Commercial Operations. Ms. Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors.

  • Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association
    PR Newswire

    Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a California-based independent physician association (IPA) to provide its liquid biopsy testing services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.

  • Biocept to Present at the 22nd Annual BIO CEO & Investor Conference
    PR Newswire

    Biocept to Present at the 22nd Annual BIO CEO & Investor Conference

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference on Monday, February 10, 2020, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference is being held at the New York Marriott Marquis in New York City.

  • Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
    PR Newswire

    Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that its Target Selector™ assays are now available to physicians in order to evaluate the cerebrospinal fluid (CSF) of their patients for the presence of circulating tumor cells (CTCs) and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system (CNS) metastases. The presence of tumor cells in CSF may be an indicator of brain metastases, which occurs when cancer has spread into the CNS. Up to 30% and 36% of patients diagnosed with breast and lung cancer, respectively, will develop brain metastases.

  • How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio?

    If you're interested in Biocept, Inc. (NASDAQ:BIOC), then you might want to consider its beta (a measure of share...

  • Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type
    PR Newswire

    Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded U.S. Patent No. 10,527,611 titled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS from the United States Patent and Trademarks Office (USPTO). The newly issued patent covers devices for the detection of cells of interest, including circulating tumor cells (CTCs), that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis. This patent includes any biological sample type of interest and includes the use of single antibodies or cocktails of antibodies.

  • Biocept Announces Closing of $10.0 Million Underwritten Public Offering
    PR Newswire

    Biocept Announces Closing of $10.0 Million Underwritten Public Offering

    Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced that on December 11, 2019 it closed its previously announced underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 24,600,000 shares of its common stock. Each share of common stock or pre-funded warrant was sold together with one warrant to purchase one share of common stock at a combined price to the public of $0.405 per share and warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, were approximately $10.0 million. In addition, Biocept granted to Maxim Group LLC a 45-day option to purchase up to an additional 3,690,000 shares of common stock and/or warrants to purchase up to 3,690,000 shares of common stock, at the public offering price less discounts and commissions, of which Maxim Group LLC has partially exercised its option to purchase warrants to purchase up to 1,927,500 shares of common stock.

  • Benzinga

    The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

    The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • PR Newswire

    Biocept Announces Pricing of $10.0 Million Underwritten Public Offering

    Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 24,600,000 shares of the Company's common stock. Each share of common stock or pre-funded warrant is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $0.405 per share and warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10.0 million.

  • Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®
    PR Newswire

    Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that clinical data supporting the use of its Target Selector™ CTC platform as an aid in the monitoring and treatment of breast cancer will be presented in a poster session at the 2019 San Antonio Breast Cancer Symposium® (SABCS). The Symposium is being held December 10-14, at the Henry B. Gonzalez Convention Center in Austin, Texas. Information about the SABCS can be found at www.sabcs.org/2019-SABCS.

  • Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
    PR Newswire

    Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer

    SAN DIEGO, Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the commercial availability of its Target Selector™ pan-TRK assay  for the detection of TRK proteins. With the Biocept assay, a simple blood sample can help inform physicians on the potential presence of NTRK fusions, which are actionable biomarkers that can be used to qualify patients for treatment with TRK inhibitor therapies.

  • Biocept Reports Third Quarter 2019 Financial Results
    PR Newswire

    Biocept Reports Third Quarter 2019 Financial Results

    - Revenues reached a record $1.5 million , up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter ...

  • Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe
    PR Newswire

    Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe

    SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conformité Européene) IVD Marks and availability of its CEE-Sure® Blood Collection Tube and CEE-Sure® Sample Collection Shipping Kit in Europe. The CE Marks confirm that the Company's CEE-Sure® products, designed to collect and transport blood and other liquid biopsy specimens, meet the requirements of the European In-Vitro Diagnostic Devices Directive (98/79/EC), which now allows Biocept to commercialize its tubes and collection/shipping kits throughout the European Union and other CE Mark geographies.

  • Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019
    PR Newswire

    Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019

    SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
    PR Newswire

    Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting

    Data highlight strong analytical and clinical performance of Biocept's proprietary technologies, including circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) capture, and molecular testing ...

  • Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To You
    Simply Wall St.

    Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To You

    Mike Nall became the CEO of Biocept, Inc. (NASDAQ:BIOC) in 2013. This analysis aims first to contrast CEO compensation...

  • Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
    PR Newswire

    Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE

    SAN DIEGO, Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed journal article featuring analytical validation results demonstrating the high sensitivity of the Company's Target Selector™ testing for EGFR, BRAF, and KRAS mutations in plasma circulating tumor DNA (ctDNA).

  • Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
    PR Newswire

    Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform

    The patent provides intellectual property protection for the Company's Switch-Blocker technology, which is core to Biocept's Target Selector™ assays for molecular analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).

  • Biocept to Present at Two Investment Conferences in September
    PR Newswire

    Biocept to Present at Two Investment Conferences in September

    SAN DIEGO , Sept. 3, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
    PR Newswire

    High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer

    Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant ...

  • Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
    PR Newswire

    Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells

    New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients ...

  • Biocept Reports Second Quarter 2019 Financial Results
    PR Newswire

    Biocept Reports Second Quarter 2019 Financial Results

    - Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 - Revenues for the first six-month of 2019 increased 36% and commercial samples increased ...

  • ACCESSWIRE

    Biocept, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Biocept, Inc. (NASDAQ: BIOC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 PM Eastern ...

  • Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
    PR Newswire

    Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019

    SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
    PR Newswire

    Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®

    SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into a Laboratory Services Provider Agreement with Beacon Laboratory Benefit Solutions, Inc. (BeaconLBS®), a nationally recognized premier provider of laboratory benefit management technology solutions to health and managed care companies in the United States. BeaconLBS administers laboratory benefit management programs for health plans to improve test ordering efficiency, test appropriateness, affordability, and quality of care for health plan members.